Loading...
RAS Pathway Drug Competition And Financing Risks Will Dominate Yet Long-Term Potential Remains
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
105.3%7D
-6.2%1Y
105.3%7D
-6.2%You can edit this narrative until Dec 15 8:10 AM. Then, changes will post as Updates.